SCHEMBL6979333

SCHEMBL6979333

Cc1ccc(COc2cccc(F)c2)c(Cl)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 1/20 0.46
NR4A2 P43354 2/20 0.46
NR4A1 P22736 1/20 0.46
NR4A3 Q92570 1/20 0.46
MAOB P27338 7/20 0.46
SLC6A2 P23975 2/20 0.43
SLC6A4 P31645 2/20 0.43
DCPS Q96C86 1/20 0.43
HTR1A P08908 1/20 0.43
SLC6A3 Q01959 1/20 0.43
MAOA P21397 1/20 0.43
MRGPRX4 Q96LA9 1/20 0.42
RAB9A P51151 2/20 0.42
GRM5 P41594 1/20 0.42
NPC1 O15118 1/20 0.42
DAO P14920 1/20 0.42
ACHE P22303 1/20 0.42
MEN1 O00255 1/20 0.41
POLB P06746 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13712203 0.83 MAOB (0.47) HTR6NR4A2NR4A1NR4A3MAOB
SCHEMBL2983086 0.82 MAOB (0.50) HTR6NR4A2NR4A1NR4A3MAOB
SCHEMBL6957885 0.82 MAOB (0.46) HTR6NR4A2NR4A1NR4A3MAOB
SCHEMBL6979144 0.82 APP (0.44) HTR6NR4A2NR4A1NR4A3MAOB
SCHEMBL13709217 0.82 NR4A2 (0.43) HTR6NR4A2NR4A1NR4A3MAOB
SCHEMBL26377963 0.81 NR4A2 (0.60) HTR6NR4A2MAOBSLC6A2SLC6A4
SCHEMBL14380761 0.80 FFAR1 (0.43) HTR6NR4A2NR4A1NR4A3MAOB
SCHEMBL14380641 0.79 DCPS (0.43) HTR6NR4A2NR4A1NR4A3MAOB
SCHEMBL6956760 0.79 MAOB (0.46) HTR6NR4A2NR4A1NR4A3MAOB
SCHEMBL22964337 0.78 NR4A2 (0.50) NR4A2NR4A1NR4A3MAOBMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1854789-B1 QUINAZOLINE DERIVATIVE HAVING TYROSINE KINASE INHIBITORY ACTIVITY SHIONOGI & CO (JP) 2013-10-09 EP disclosed
US-8349857-B2 Quinazoline derivatives having tyrosine kinase inhibitory activity SHIONOGI & CO., LTD. (JP) 2013-01-08 US disclosed
US-20120123114-A1 QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2012-05-17 US disclosed
US-7501427-B2 Quinazoline analogs as receptor tyrosine kinase inhibitors ARRAY BIOPHARMA, INC. (US) 2009-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120123114-A1 QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY ERBB2, EGFR, ABL1 HTR6 755/4885NR4A2 745/4885NR4A1 876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.